On May 28, 2024, Omega Therapeutics, Inc. (company) and Yan Moore, M.D., the company?s Chief Medical Officer, agreed to terminate his employment effective as of May 31, 2024. In connection with the termination, Dr. Moore entered into a separation agreement with the Company containing a release of claims that provides for the severance payments and benefits set forth in his employment agreement with the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.07 USD | -7.59% | -14.81% | -31.23% |
06-24 | Omega Therapeutics, Inc. Appoints Richard N. Kender to Board of Directors | CI |
06-18 | Raymond James Initiates Omega Therapeutics at Outperform Rating With $12 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.23% | 114M | |
+19.41% | 45.51B | |
+38.65% | 38.13B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- OMGA Stock
- News Omega Therapeutics, Inc.
- Omega Therapeutics, Inc. Announces Termination of Yan Moore as Chief Medical Officer